Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Phase 2
2(33.3%)
6Total
Phase 1(4)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT00290615Phase 2Completed

Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery

Role: lead

NCT00586092Phase 1Completed

A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors

Role: lead

NCT00253565Phase 1Completed

Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors

Role: lead

NCT00597506Phase 2Completed

Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus

Role: lead

NCT00849550Phase 1Completed

Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.

Role: lead

NCT01055795Phase 1Completed

Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors

Role: lead

All 6 trials loaded